Pathologic response after neoadjuvant chemotherapy in resectable non-small cell lung cancers: proposal for the use of “major pathologic response” as a surrogate endpoint

Improvements in outcomes for patients with resectable lung cancers have plateaued. Clinical trials in this disease using overall survival as the primary endpoint require a decade or longer to complete, are expensive, and limit innovation. A surrogate for survival, such as pathologic response to neoa...

Full description

Saved in:
Bibliographic Details
Published in:Lancet Oncol
Main Authors: Hellmann, Matthew D., Chaft, Jamie E., William, William N., Rusch, Valerie, Pisters, Katherine M.W., Kalhor, Neda, Pataer, Apar, Travis, William D., Swisher, Stephen G., Kris, Mark G.
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4734624/
https://ncbi.nlm.nih.gov/pubmed/24384493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70334-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items